Español 
Deutsch 
Français 
MSCI World Index (MSC)
NASDAQ Composite (NASDAQ)
FTSE China A50 Index (FGI)
STOXX Europe 600 (SIX)
Nikkei 300 (OSA)
NIFTY 50 (NSE)
DAX Performance Index (XETRA)
FTSE 100 (FGI)
CAC 40 (EURONEXT)
Borregaard ASA (BRG.OL)
NOK151.40
+2.00 (+1.34%)
NO OSL Basic Materials Chemicals - Specialty
Address
Hjalmar Wessels vei 6 1701
Sarpsborg, NO
Sarpsborg, NO
CEO
Tom Erik Foss-Jacobsen
Website
borregaard.com
IPO
2012-10-18
ISIN NO0010657505
Also trades on
Oslo Stock Exchange · BRG.OL (NOK)
Other OTC · BRGAY (USD)
Other OTC · BRRDF (USD)
Description
Borregaard ASA, established in 2012 and headquartered in Sarpsborg, Norway, is a global enterprise focused on the development, production, and marketing of specialized biomaterials, biochemicals, and biofuels. Its market presence extends across Norway, the broader European region, the United States, Asia, and various other international territories. The company's operations are structured around three distinct divisions: BioSolutions, BioMaterials, and Fine Chemicals. The BioSolutions segment provides biopolymers crucial for numerous applications, including agrochemicals, battery manufacturing, industrial binding, and construction. This division also supplies biovanillin to the flavor and fragrance industries, as well as the food and beverage sector. In the BioMaterials segment, Borregaard offers specialty cellulose, utilized as a raw material in the production of items such as cellulose ethers, cellulose acetate, and other specialized products. It further manufactures cellulose fibrils for diverse industrial purposes. Lastly, the Fine Chemicals segment delivers fine chemical intermediates, particularly for contrast agents, in addition to bioethanol.
Market Cap & Enterprise Value
Merger & Acquisition History
No mergers or acquisitions recorded for this company.
Technical Outlook
Loading outlook…
Loading forecast...
Signal Summary
Loading…
| Indicator | 1D | 1W | 2W | 3W | 1M |
|---|
Each column is computed on that timeframe's candles (1D = daily, 1W ≈ weekly, 1M ≈ monthly), not on the same last day. ▲ bullish · ▼ bearish · — neutral. The Net row counts signals per column; hover any cell (or the indicator name) to see the exact rule behind it.
Day Score & sub-scores
Statistical fingerprint & regime detail
Conditional historical analysis
Customize analysis (advanced)
Indicative levels generated algorithmically. Not financial advice.
Risk Profile
Loading risk profile…
Price Chart
NOK151.40
+2.00 (+1.34%)
Loading historical data…
Volume Profile
Loading…
Liquidity & share structure
Average Volume
149.6K
Beta
0.57
Float Shares
80.14M
Free Float %
80.2%
Price Performance
| 1D | 5D | 1M | 3M | 6M | YTD | 1Y | 3Y | 5Y | 10Y | Max |
|---|---|---|---|---|---|---|---|---|---|---|
| -2.59% | -4.55% | -6.30% | -19.23% | -24.84% | -27.37% | -23.80% | -22.48% | -24.52% | +124.00% | +589.86% |
Rolling Volatility
Loading…
Drawdown
Loading…
Relative Strength
Loading…
Monthly Returns Heatmap
From
To
Loading…
Annual Monthly Returns
Loading…
Daily Returns Distribution
Loading histogram data…
Revenue flow
Revenue by geography
Revenue by segment
From
To
Revenue composition
From
To
By product
By geography
Financial Statements
Select metrics from the tables below to build your comparison.
Income Statement
Balance Sheet
Cash Flow Statement
Key Metrics
Financial Ratios
Employees
Financial Growth (CAGR)
Market Data
Price Targets & DCF
Current price
151.40
DCF (Unlevered)
150.24
-0.8%
DCF (Levered)
110.19
-27.2%
DCF figures are point estimates: small changes in growth or discount-rate assumptions move them materially. Read them as a reference, not a precise target.
Ratings Trend (MoM)
50% Bullish
| Rating | 2026-05 | Change |
|---|---|---|
| Strong Buy | 0 | 0 |
| Buy | 3 | 0 |
| Hold | 3 | -1 |
| Sell | 0 | 0 |
| Strong Sell | 0 | 0 |
Quality scores
Altman Z-Score
3.68
Safe zone
Piotroski F-Score
7 / 9
Strong
MOAT Score
4 / 10
Developing
Composite Rating
B+
Overall Score
3 / 5
Medium
DCF Score
4 / 5
High
ROE Score
4 / 5
High
ROA Score
5 / 5
High
D/E Score
2 / 5
Medium
P/E Score
2 / 5
Medium
P/Book Score
2 / 5
Medium
Operational MOAT
✗ Below peers
-
Revenue growth Chemicals - Specialty: +4.7%+1.0% Q1'26: -1.5% (vs Q1'25)
-
EPS growth Chemicals - Specialty: +13.2%-24.6% Q1'26: -27.8% (vs Q1'25)
-
FCF margin FCF growth · Chemicals - Specialty: +44.1%+9.4% Q1'26: -1.4% (vs Q1'25)
-
EBIT margin Chemicals - Specialty: +8.8%+16.9% ★ Q1'26: +12.9% (vs Q1'25)
-
ROIC Chemicals - Specialty: +5.6%+11.1% ★ Q1'26: +9.3% (vs Q1'25)
-
Share dilution Chemicals - Specialty: +0.1%0.0% Q1'26: +0.2% (vs Q1'25)
-
Debt / EBITDA Net debt/EBITDA · Chemicals - Specialty: 0.18×1.17× Q1'26: 1.33× (vs Q1'25)
Valuation Multiples
From
To
Price Forecast (3Y)
From
To
Theoretical Return — If Invested Today
* These projections are based on analyst consensus estimates and user-defined valuation multiples. This table is for informational purposes only and does not constitute a recommendation to buy or sell any security. Past performance is not indicative of future results.
Consensus Estimates
| Metric |
Dec 2012 actual |
Dec 2013 actual |
Dec 2014 actual |
Dec 2015 actual |
Dec 2016 actual |
Dec 2017 actual |
Dec 2018 actual |
Dec 2019 actual |
Dec 2020 actual |
Dec 2021 actual |
Dec 2022 actual |
Dec 2023 actual |
Dec 2024 actual |
Dec 2025 actual |
Dec 2026 4 Rev. Ana. 4 EPS Ana. |
Dec 2027 5 Rev. Ana. 4 EPS Ana. |
Dec 2028 4 Rev. Ana. 4 EPS Ana. |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Revenue |
3.94B
est: 4.01B (-1.7%)
|
4.00B
est: 3.94B (+1.5%)
|
3.94B
est: 4.04B (-2.5%)
|
4.16B
est: 4.12B (+1.1%)
|
4.49B
est: 4.44B (+1.2%)
|
4.62B
est: 4.60B (+0.4%)
|
4.79B
est: 4.75B (+0.8%)
|
5.06B
est: 5.06B (+0.1%)
|
5.33B
est: 5.18B (+2.9%)
|
5.81B
est: 5.56B (+4.3%)
|
6.78B
est: 6.86B (-1.2%)
|
7.02B
est: 7.24B (-3.0%)
|
7.50B
est: 7.57B (-0.8%)
|
7.58B
est: 7.61B (-0.4%)
|
7.83B
7.67B – 7.98B
+2.8% YoY
|
8.23B
7.93B – 8.44B
+5.1% YoY
|
8.65B
8.58B – 8.72B
+5.2% YoY
|
| EBITDA |
712.00M
est: 944.19M (-24.6%)
|
733.00M
est: 618.64M (+18.5%)
|
764.00M
est: 674.35M (+13.3%)
|
802.00M
est: 676.99M (+18.5%)
|
1.03B
est: 810.41M (+27.2%)
|
1.05B
est: 1.02B (+3.8%)
|
926.00M
est: 1.06B (-12.8%)
|
976.00M
est: 979.97M (-0.4%)
|
1.06B
est: 922.77M (+14.3%)
|
1.36B
est: 934.38M (+45.0%)
|
1.68B
est: 998.41M (+68.3%)
|
1.79B
est: 1.88B (-5.0%)
|
1.86B
est: 1.95B (-4.8%)
|
1.87B
est: 1.97B (-5.4%)
|
2.03B
1.99B – 2.07B
+2.8% YoY
|
2.13B
2.06B – 2.19B
+5.1% YoY
|
2.24B
2.22B – 2.26B
+5.2% YoY
|
| EBIT |
491.00M
est: 643.90M (-23.7%)
|
502.00M
est: 463.49M (+8.3%)
|
463.00M
est: 514.23M (-10.0%)
|
533.00M
est: 473.48M (+12.6%)
|
746.00M
est: 573.64M (+30.0%)
|
744.00M
est: 783.84M (-5.1%)
|
598.00M
est: 761.94M (-21.5%)
|
554.00M
est: 608.91M (-9.0%)
|
578.00M
est: 582.47M (-0.8%)
|
935.00M
est: 589.80M (+58.5%)
|
1.21B
est: 630.22M (+92.2%)
|
1.30B
est: 1.25B (+3.3%)
|
1.31B
est: 1.30B (+0.6%)
|
1.28B
est: 1.32B (-3.1%)
|
1.35B
1.33B – 1.38B
+2.8% YoY
|
1.42B
1.37B – 1.46B
+5.1% YoY
|
1.50B
1.48B – 1.51B
+5.2% YoY
|
| Net Income |
273.00M
est: 332.09M (-17.8%)
|
335.00M
est: 271.02M (+23.6%)
|
334.00M
est: 343.85M (-2.9%)
|
386.00M
est: 346.80M (+11.3%)
|
555.00M
est: 415.43M (+33.6%)
|
566.00M
est: 575.44M (-1.6%)
|
476.00M
est: 585.95M (-18.8%)
|
417.00M
est: 503.20M (-17.1%)
|
436.00M
est: 435.29M (+0.2%)
|
692.00M
est: 440.76M (+57.0%)
|
892.00M
est: 470.97M (+89.4%)
|
870.00M
est: 800.00M (+8.8%)
|
823.00M
est: 835.49M (-1.5%)
|
620.00M
est: 883.29M (-29.8%)
|
807.40M
577.81M – 910.03M
-8.6% YoY
|
1.00B
965.54M – 1.03B
+23.9% YoY
|
1.10B
751.50M – 1.25B
+9.6% YoY
|
| SGA |
415.00M
est: 466.51M (-11.0%)
|
412.00M
est: 852.34M (-51.7%)
|
389.00M
est: 928.90M (-58.1%)
|
432.00M
est: 978.11M (-55.8%)
|
441.00M
est: 1.12B (-60.5%)
|
475.00M
est: 1.15B (-58.7%)
|
524.00M
est: 1.21B (-56.8%)
|
562.00M
est: 1.33B (-57.7%)
|
682.00M
est: 1.34B (-49.2%)
|
658.00M
est: 1.36B (-51.6%)
|
801.00M
est: 1.45B (-44.8%)
|
804.00M
est: 660.17M (+21.8%)
|
823.00M
est: 687.04M (+19.8%)
|
—
est: 693.77M (-100.0%)
|
713.25M
699.36M – 727.12M
+2.8% YoY
|
749.73M
723.12M – 769.39M
+5.1% YoY
|
788.46M
781.90M – 795.02M
+5.2% YoY
|
| EPS |
2.76
est: 3.33 (-17.1%)
|
3.35
est: 3.17 (+5.8%)
|
3.34
est: 3.53 (-5.4%)
|
3.86
est: 3.40 (+13.6%)
|
5.55
est: 5.25 (+5.7%)
|
5.66
est: 5.40 (+4.8%)
|
4.78
est: 4.67 (+2.3%)
|
4.19
est: 4.43 (-5.5%)
|
4.38
est: 4.69 (-6.7%)
|
6.95
est: 7.05 (-1.5%)
|
8.95
est: 8.69 (+2.9%)
|
8.73
est: 8.02 (+8.9%)
|
8.25
est: 8.40 (-1.8%)
|
6.22
est: 8.88 (-30.0%)
|
7.72
5.79 – 9.12
-13.1% YoY
|
10.05
9.68 – 10.37
+30.2% YoY
|
10.82
7.54 – 12.49
+7.6% YoY
|
Historical Ratings (3M)
| Date | Rating | Overall | DCF | ROE | ROA | D/E | P/E | P/B |
|---|---|---|---|---|---|---|---|---|
| 2026-05-29 | B+ | 3/5 | 4/5 | 4/5 | 5/5 | 2/5 | 2/5 | 2/5 |
| 2026-05-28 | B+ | 3/5 | 4/5 | 4/5 | 5/5 | 2/5 | 2/5 | 2/5 |
| 2026-05-27 | B+ | 3/5 | 4/5 | 4/5 | 5/5 | 2/5 | 2/5 | 2/5 |
| 2026-05-26 | B+ | 3/5 | 4/5 | 4/5 | 5/5 | 2/5 | 2/5 | 2/5 |
| 2026-05-22 | B+ | 3/5 | 4/5 | 4/5 | 5/5 | 2/5 | 2/5 | 2/5 |
| 2026-05-21 | B+ | 3/5 | 4/5 | 4/5 | 5/5 | 2/5 | 2/5 | 2/5 |
| 2026-05-20 | B+ | 3/5 | 4/5 | 4/5 | 5/5 | 2/5 | 2/5 | 2/5 |
| 2026-05-19 | B+ | 3/5 | 4/5 | 4/5 | 5/5 | 2/5 | 2/5 | 2/5 |
| 2026-05-18 | B+ | 3/5 | 4/5 | 4/5 | 5/5 | 2/5 | 2/5 | 2/5 |
| 2026-05-15 | B+ | 3/5 | 4/5 | 4/5 | 5/5 | 2/5 | 2/5 | 2/5 |
| 2026-05-13 | B+ | 3/5 | 4/5 | 4/5 | 5/5 | 2/5 | 2/5 | 2/5 |
| 2026-05-12 | B+ | 3/5 | 4/5 | 4/5 | 5/5 | 2/5 | 2/5 | 2/5 |
| 2026-05-11 | B+ | 3/5 | 4/5 | 4/5 | 5/5 | 2/5 | 2/5 | 2/5 |
| 2026-05-08 | B+ | 3/5 | 4/5 | 4/5 | 5/5 | 2/5 | 2/5 | 2/5 |
| 2026-05-07 | B+ | 3/5 | 4/5 | 4/5 | 5/5 | 2/5 | 2/5 | 2/5 |
| 2026-05-06 | B+ | 3/5 | 4/5 | 4/5 | 5/5 | 2/5 | 2/5 | 2/5 |
| 2026-05-05 | B+ | 3/5 | 4/5 | 4/5 | 5/5 | 2/5 | 2/5 | 2/5 |
| 2026-05-04 | B+ | 3/5 | 4/5 | 4/5 | 5/5 | 2/5 | 2/5 | 2/5 |
| 2026-04-30 | B+ | 3/5 | 4/5 | 4/5 | 5/5 | 1/5 | 2/5 | 2/5 |
| 2026-04-29 | B+ | 3/5 | 4/5 | 4/5 | 5/5 | 1/5 | 2/5 | 2/5 |
| 2026-04-28 | B+ | 3/5 | 4/5 | 4/5 | 5/5 | 1/5 | 2/5 | 2/5 |
| 2026-04-27 | B+ | 3/5 | 4/5 | 4/5 | 5/5 | 1/5 | 2/5 | 2/5 |
| 2026-04-24 | B | 3/5 | 4/5 | 4/5 | 5/5 | 1/5 | 1/5 | 2/5 |
| 2026-04-23 | B | 3/5 | 4/5 | 4/5 | 5/5 | 1/5 | 1/5 | 2/5 |
| 2026-04-22 | B | 3/5 | 4/5 | 4/5 | 5/5 | 1/5 | 1/5 | 2/5 |
| 2026-04-21 | B | 3/5 | 4/5 | 4/5 | 5/5 | 1/5 | 1/5 | 2/5 |
| 2026-04-20 | B | 3/5 | 4/5 | 4/5 | 5/5 | 1/5 | 1/5 | 2/5 |
| 2026-04-17 | B | 3/5 | 4/5 | 4/5 | 5/5 | 1/5 | 1/5 | 2/5 |
| 2026-04-16 | B | 3/5 | 4/5 | 4/5 | 5/5 | 1/5 | 1/5 | 2/5 |
Owner Earnings
Owner's Earnings (history)
From
To
Owner alignment
Owner's Earnings TTM
552.04M
OE per share TTM
5.53
Owner's Yield
3.87%
Maintenance CapEx ratio
70.64%
Maint CapEx / Avg PPE
76.0%
Ownership Overview
Ownership breakdown
Ownership breakdown not available.
At a glance
Institutional holders
—
Total invested
—
Insider transactions (90d)
0
Beneficial owners (>5%)
0
Beneficial owners (>5%)
No beneficial ownership filings recorded.
Institutional Activity (13F)
Institutional ownership trend
Institutional history not available.
Top institutional holders
Top holders not available.
ETF Ownership
Top ETFs holding this stock
Held by 39 ETFs in our universe
| # | ETF | Weight | Est. AUM exposure | TER |
|---|---|---|---|---|
| 1 | abrdn International Small Cap Active ETF ASCI | 1.39% | 1.09M | 1.05% |
| 2 | RockCreek Global Equality ETF RCGE | 0.50% | 477.9K | 0.95% |
| 3 | WisdomTree International SmallCap Dividend Fund DLS | 0.08% | 841.9K | 0.58% |
| 4 | WisdomTree Dynamic International SmallCap Equity ETF DDLS | 0.08% | 341.9K | 0.48% |
| 5 | Vanguard FTSE All-World ex-US Small-Cap ETF VSS | 0.04% | 5.10M | 0.06% |
| 6 | WisdomTree Europe Quality Dividend Growth Fund EUDG | 0.04% | 23.9K | 0.58% |
| 7 | Fidelity Europe Equity Research Enhanced UCITS ETF Accum Shs EUR FEUR.L | 0.03% | 36.9K | 0.25% |
| 8 | Avantis International Small Cap Equity ETF AVDS | 0.02% | 72.1K | 0.30% |
| 9 | iShares International Dividend Growth ETF IGRO | 0.02% | 225.4K | 0.15% |
| 10 | WisdomTree International Equity Fund DWM | 0.01% | 76.1K | 0.48% |
Insider Activity
Insider Activity — Latest Quarter
No insider activity available.
Insider buys vs sells (history)
Insider history not available.
Recent insider transactions
No recent insider transactions.
Executive team
Top executives
EBIT / Employee
1.09M
Shares Outstanding
99.94M
Executive compensation
Executive compensation (annual)
Executive compensation not available.
CEO compensation breakdown
No CEO compensation history available.
Proxy statements
Proxy statements (DEF 14A)
No proxy statements available for this company yet.
Recent SEC filings
Recent SEC filings
No SEC filings available for this company yet.
Executive team
| Name | Title | Compensation | Gender |
|---|---|---|---|
| Knut-Harald Bakke | Executive Vice President of BioSolutions | 6M | male |
| Tom Erik Foss-Jacobsen | Chief Executive Officer | 6M | male |
| Kari Strande | Senior Vice President of Human Resources | 5M | female |
| Ole Gunnar Jakobsen | Executive Vice President of Manufacturing & Technology | 4M | male |
| Per Bjarne Lyngstad | Chief Financial Officer | 4M | male |
| Gisle Løhre Johansen | Executive Vice President of Speciality Cellulose & Fine Chemicals | 4M | male |
| Rolf Sveinung Heggen | General Counsel | 4M | male |
| Kristin Misund | Senior Vice President of R&D and Business Development | 3M | female |
| Dag Arthur Aasbø | Senior Vice President of Public Affairs & Sustainability | 3M | male |
| Liv Longva | Senior Vice President of Procurement & Strategic Sourcing | 3M | female |
| Tuva Barnholt | Senior Vice President of Strategic Sourcing | 2M | female |
| Lotte Kvinlaug | Investor Relations Officer | — | female |
ESG Score History
No data available for this company.
Senate Trading Activity
No Senate trading activity found for this company.
House Trading Activity
No House trading activity found for this company.
Market share among peers
Peer comparison — filtered group (TTM)
Your opinion
Share your view on this stock and instantly see how the community has voted over the last 6 months.
Community Opinion for BRG.OL
Short-term intention
Target Price Distribution
These are community opinions and do not constitute buy or sell advice to act on. The results shown are based on aggregated opinions and are not an investment recommendation, nor do they intend to influence any investment decision.
